Petrushevska marinkovikj, Sanja

Preferred name
Petrushevska marinkovikj, Sanja
Official Name
Petrushevska marinkovikj, Sanja
Translated Name
Petrusevska Marinkovic Sanja
Main Affiliation
Email
sanjapm@yahoo.com
Researcher ID
https://orcid.org/0009-0009-3224-2016

Settings

Now showing 1 - 4 of 4
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Avascular Necrosis of the Hip Joint and Femoral Head Related with Long COVID-19 or Post-COVID-19: Case Report Study
    (Scientific Foundation SPIROSKI, 2024-02-25)
    ;
    ;
    Jovanovski, Mario
    ;
    Savin, Tanja
    ;
    Novachkova-Siljanovska, Bojana
    <jats:p>BACKGROUND: Post-COVID conditions can include a wide range of ongoing health problems. As a consequence of long COVID-19 or post-COVID-19 an increase in osteonecrosis has been detected in different series of patients. CASE PRESENTATION: We present two patients diagnosed with COVID-19 and pneumonia, one with moderate and the other with severe clinical picture. They were treated with corticosteroid equivalent to prednisolone 993.5 mg (400–1587 mg) which correlates with steroid dose documented in the literature as causative for avascular necrosis (ANV) in patients with COVID-19. After the mean time of 65 days, due to pain in the groin and difficulty in movement, magnetic resonance imaging (MRI) was performed in both patients and AVN was diagnosed. Compared to our results, the literature records a longer time required for the development of AVN in patients without COVID-19, which is 6–36 months. This indicates the potency of the virus itself to cause disturbances in the microcirculation, and thus the development of AVN. The bone damage correlates with the degree of inflammation and the severity of the clinical picture. CONCLUSION: After a course of COVID-19 as part of a long COVID-19, ANV should be considered a possible complication, especially in patients who have clinical manifestations. Early detection of AVN and diagnosis using MRI on clinical suspicion would help early intervention with bisphosphonate therapy in patients with osteonecrosis of the hip. If the disease is detected in the more advanced stage, it is necessary to perform a surgical intervention and even a possible hip replacement.</jats:p>
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    ANTIPHOSPHOLIPID-LIKE SYNDROME INDUCED BY COVID19: A CASE REPORT STUDY
    (Macedonian Association of Anatomists, 2024)
    ;
    Anastasovski, Ankcia
    ;
    Abstract Many patients with severe COVID-19 present with coagulation abnormalities associated with severe infections, such as disseminated intravascular coagulation or trombotic mycroangiopathy. That’s why is important to pay attention to the differential diagnoses of COVID-19 and other diseases following thrombotic events. Antiphospholipid syndrome is an autoimmune disorder characterized by thrombosis. The diagnosis criteria for antiphospholipid syndrome are based on the detection of abnormal levels of at least one of the most common antiphospholipid antibodies . In this study, we discuss the relationship between COVID-19, antiphospholipid syndrome and antiphospholipid syndrome -like phenomenon, and thrombosis that may occur. We present a 60-year-old woman hospitalized for COVID-19 and pneumonia with a moderately severe clinical picture. During the hospitalization under anticoagulant therapy, she developed coagulation disorders with prolonged active partial thromboplastin time, positive lupus anticoagulant and positive beta-2glycoprotein. The coagulation disorder is in addition to antiphospholipid syndrome, which is associated with the possibility of bleeding in the patient. Elevated levels of the isotypes of antiphospholipid antibodies in COVId-19 patients create antiphospholipid syndrome-like condition. Considering the high rate of mortality due to coagulation abnormalities and thrombosis among COVID-19 patients, it is important to pay attention to the differential diagnoses of COVID-19 and other diseases following thrombotic events, as well as their implication on the therapeutic approach to patients. Current data recommend the use of prophylactic anticoagulation with low molecular weight heparin in hospitalized patients with COVID-19 regardless of the severity of the clinical picture.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Pulmonary embolism in a patient with COVID-19 pneumonia despite satisfying anticoagulation status
    (Department of Anesthesia and Reanimation, Faculty of Medicine, "Ss Cyril and Methodius" University, Skopje, R. N. Macedonia, 2022-12)
    Jovanoski M
    ;
    ;
    ;
    ;
    Introduction: COVID-19 disease is a disease related to many complications, some of them are life threatening. Venous thromboembolism is one of the cardiovascular causes (the third in mortality in the group of cardiovascular diseases), which can lead to serious morbidity and even mortality. Aim: To present the fact that a quality anticoagulation therapy is not always a 100 percent safe mechanism of dealing with VTE. Case Report: This case report is about a patient which was presented with a clinical condition related to COVID-19 bilateral bronchopneumonia. As such, she was treated with all the necessary medications, but after a VTE occurred as one of the complications, we had to upgrade the doses of anticoagulation to a therapeutic status. The CT angiography showing lobar and subsegmental pulmonary embolism was the gold standard to confirm the diagnosis. The effect of the LWMH which was used for the VTE was controlled by measuring the anti-Xa blood level. A further correction of the doses and types of antibiotics had to be done because of medications related thrombocytopenia which made the condition even more difficult to fight with. Conclusion: Using the antiXa as a tool to control the anticoagulation status in VTE patients can be a valuable thing to do. However, we must be always thorough in observing the clinical condition of the patient and be aware of the complications which can happen.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Analysis of Antibiotic Treatment and Microbiological Findings and Its Implication on Outcome in Patients with Parapneumonic Effusions
    (Scientific Foundation SPIROSKI, 2024-06-02)
    <jats:p>BACKGROUND: Parapneumonic effusion (PPE), as a complication of community-acquired pneumonia, sometimes progresses into complicated PPE (CPPE) and empyema, thus becoming a significant clinical problem. There is a lack of guidelines for antibiotic therapy and reports on local microbiological status and resistance of microorganisms. AIM: Тhe paper is focused on the analysis of antibiotic therapy and microbiological findings that are affecting patient outcomes and length of treatment. METHODS: We analyzed 94 patients, 50 with uncomplicated PPE (UCPPE) and 44 with CPPEs. RESULTS: More patients (59.57%) were male, average age 53.82 ± 17.5 years. Alcoholism was the most common comorbidity in patients with CPPE registered in 25% of patients. A positive pleural punctate culture was present in 31.82% of patients with CPPE. Peptostreptococcus was most often isolated in 28.57%. Blood culture was positive in 12.76% of patients. Most of the patients were treated with combined therapy that also covered anerobes (64.89%). Statistical differences existed in terms of days of hospital treatment with a longer hospital stay for patients with CPPE (p < 0.0001). The average time of hospital treatment in patients with UCPPE was 15 days, and in patients with CPPE, it was 21 days. CONCLUSION: As soon as a pleural infection is noted, patients should receive antibiotic therapy, which should be based on pleural fluid culture. Anerobic coverage is required. In this way, the development of CPPE and empyema will be prevented, and thus, mortality and long hospital stays will be reduced.</jats:p>